1-2-dilauroylphosphatidylcholine and Diabetes-Mellitus

The human nuclear receptor liver receptor homolog-1 (LRH-1) has an important role in controlling lipid and cholesterol homeostasis and is a potential target for the treatment of diabetes and hepatic diseases. LRH-1 is known to bind phospholipids, but the role of phospholipids in controlling LRH-1 activation remains highly debated. Here we describe the structure of both apo LRH-1 and LRH-1 in complex with the antidiabetic phospholipid dilauroylphosphatidylcholine (DLPC). Together with hydrogen-deuterium exchange MS and functional data, our studies show that DLPC binding is a dynamic process that alters co-regulator selectivity. We show that the lipid-free receptor undergoes previously unrecognized structural fluctuations, allowing it to interact with widely expressed co-repressors. These observations enhance our understanding of LRH-1 regulation and highlight its importance as a new therapeutic target for controlling diabetes.

Topics: Crystallography, X-Ray; Diabetes Mellitus; Gene Expression Regulation; Humans; Hypoglycemic Agents; Molecular Dynamics Simulation; Nuclear Receptor Co-Repressor 2; Nuclear Receptor Coactivator 2; Phosphatidylcholines; Protein Binding; Protein Structure, Secondary; Receptors, Cytoplasmic and Nuclear